Bridgeway Capital Management’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$250K Buy
+30,000
New +$217K ﹤0.01% 965
2026
Q2
– Sell
-54,029
Closed -$339K – 1293
2026
Q1
$339K Sell
54,029
-15,000
-22% -$139K 0.01% 903
2025
Q4
$846K Buy
69,029
+10,000
+17% +$163K 0.02% 731
2025
Q3
$1.21M Sell
59,029
-40,000
-40% -$635K 0.03% 669
2025
Q2
$1.34M Hold
99,029
– – 0.03% 608
2025
Q1
$858K Sell
99,029
-55,071
-36% -$337K 0.02% 665
2024
Q4
$749K Hold
154,100
– – 0.02% 727
2024
Q3
$1.19M Hold
154,100
– – 0.03% 637
2024
Q2
$1.54M Buy
154,100
+43,100
+39% +$473K 0.04% 577
2024
Q1
$1.35M Sell
111,000
-13,700
-11% -$199K 0.03% 663
2023
Q4
$1.78M Buy
124,700
+40,600
+48% +$390K 0.04% 621
2023
Q3
$654K Buy
+84,100
New +$915K 0.02% 813

Other funds holding OPRX

Bridgeway Capital Management's OPRX Position: Q3 2026 in Review

Bridgeway Capital Management opened a new position in OptimizeRx (OPRX) in Q3 2026: 30,000 shares worth $250K. The stake represents ﹤0.01% of the portfolio and ranks #965 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in OPRX as recently as Q1 2026.

Bridgeway Capital Management first reported a position in OPRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.78M in Q4 2023. 103 funds tracked by Wall St. Rank hold OPRX as of Q3 2026.

  • Bridgeway Capital Management held 30,000 shares of OptimizeRx worth $250K as of Q3 2026.
  • OptimizeRx was a new Bridgeway Capital Management position in Q3 2026.
  • OptimizeRx made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #965 holding.
  • Bridgeway Capital Management first reported a position in OptimizeRx in Q3 2023 and has held it in 12 quarters since.
  • Bridgeway Capital Management's OptimizeRx position peaked at $1.78M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.